Company Profile
Inhibikase Therapeutics Stock Price, News & Analysis
- Ticker:
- IKT
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
2.41 USD (+0.42%)
Close
Last updated: August 6, 2026
224M USD
Market cap
Why the stock is moving
As of Aug 6, 2026, IKT closed up 0.42% at $2.41. No new same-company headline was identified in the current news window.
Company overview
Pulmonary Hypertension Company
Inhibikase Therapeutics develops IKT-001 for pulmonary arterial hypertension.
IKT-001
The candidate is a differentiated formulation of imatinib intended to retain pulmonary vascular activity while improving tolerability and long-term usability.
IMPROVE-PAH
The registrational Phase 3 IMPROVE-PAH study is enrolling internationally and evaluates pulmonary vascular resistance and clinical outcomes.
Future catalysts
Global site activation and enrollment are advancing in the Phase 3 IMPROVE-PAH study.
The FDA is reviewing an Orphan Drug designation application for IKT-001 in pulmonary arterial hypertension.
Recent news
- 01
Inhibikase Therapeutics Announces FDA Orphan Drug Designation Granted to IKT-001 for the Treatment of PAH
Source: Inhibikase Therapeutics
- 02
Inhibikase Therapeutics Announces Sale of $50 Million of Shares Through its At-the-Market (ATM) Facility
Source: Inhibikase Therapeutics
- 03
Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Source: Inhibikase Therapeutics
- 04
Inhibikase Therapeutics Announces First Quarter 2026 Financial Results and Highlights Recent Activity
Source: Inhibikase Therapeutics
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Inhibikase Therapeutics (IKT)?
Inhibikase Therapeutics (IKT) most recently closed at 2.41 USD, a +0.42% move versus the previous session.
What is the market cap of Inhibikase Therapeutics (IKT)?
Inhibikase Therapeutics currently has a market capitalization of 224M USD on BioPharmSignal.
What does Inhibikase Therapeutics do?
Pulmonary Hypertension Company Inhibikase Therapeutics develops IKT-001 for pulmonary arterial hypertension. IKT-001 The candidate is a differentiated formulation of imatinib intended to retain pulmonary vascular activity while improving tolerability and long-term usability. IMPROVE-PAH The registrational Phase 3 IMPROVE-PAH study is enrolling...
On which exchange is IKT stock listed?
Inhibikase Therapeutics (IKT) is associated with NASDAQ, United States, Biopharma.
What is IKT-001?
The FDA is reviewing an Orphan Drug designation application for IKT-001 in pulmonary arterial hypertension.
Which conditions is Inhibikase Therapeutics targeting with IKT-001?
The FDA is reviewing an Orphan Drug designation application for IKT-001 in pulmonary arterial hypertension.
How does Inhibikase Therapeutics describe recent progress with IKT-001?
The FDA is reviewing an Orphan Drug designation application for IKT-001 in pulmonary arterial hypertension.
What is IMPROVE-PAH?
IMPROVE-PAH The registrational Phase 3 IMPROVE-PAH study is enrolling internationally and evaluates pulmonary vascular resistance and clinical outcomes.